



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 09/676,053)	Confirmation No: 2480
)	
Inventor: Dolly, et al)	Art Unit: 1645
)	
Filed: September 28, 2000)	
)	
For: Modification of)	
Clostridial Toxins)	
For Use as a)	
Transport Protein)	
)	
Examiner: Zeman, Robert A.)	

**POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST
AND REVOCATION OF PRIOR POWERS**

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:


This Power of Attorney is being refilled to correct an error made in a previous POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST, AND REVOCATION OF PRIOR POWERS, in which the Assignee's name was erroneously listed as Invent Dublin City University, a nonexistent entity, rather than the correct assignee, Invent DCU Limited. An assignment correcting the erroneous previous assignment has been filed and was recorded at the United States Patent and Trademark Office on December 12, 2008 at Reel 022102 and Frame 0979. The right of Invent DCU Limited to take action pursuant to 37 CFR 3.73 is established in a separate document filed herewith, and entitled "ESTABLISHMENT OF RIGHT TO TAKE ACTION PURSUANT TO 37 CFR 3.73(b)".

As owner of the entire right, title, and interest in the above identified patent application, Invent DCU Limited revokes all prior powers of attorney and appoints the attorneys associated with Customer Number 33197 (the law firm of Stout, Uxa, Buyan & Mullins, LLP,) with full power of substitution and revocation, to prosecute and transact all business in the United States Patent and Trademark Office connected therewith.

Please address all correspondence to:

Carlos A. Fisher
Stout, Uxa, Buyan & Mullins, LLP
4 Venture
Suite 300
Irvine, CA 92618 USA.

I, the undersigned, declare that I am authorized to make this appointment on behalf of Allergan, and I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

	Full Name of Assignee INVENT DCU Limited	
	Post Office Address Dublin City University, Glesnevin, Dublin 9, Ireland	
	Signature of Declarant 	Date 6/2/09

Full Name of Declarant:	Richard Stokes
Title of Declarant:	Chief Executive Officer



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 09/676,053)	Confirmation No: 2480
Inventor: Dolly, et al)	
Filed: September 28, 2000)	
For: Modification of)	
Clostridial Toxins)	
For Use as a)	
Transport Protein)	
Examiner: Zeman, Robert A.)	

ESTABLISHMENT OF RIGHT TO TAKE ACTION PURSUANT TO 37 CFR 3.73(b)

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:


This document is a re-execution of a document entitled Establishment of Right to Take Action Pursuant to 37 CFR 3.73(b), filed May 28, 2007. In that document the Assignee was erroneously named as "Invent Dublin City University", a non-existent entity. As such, the original assignment is deemed null and void, and the present document corrects the error by referring to the correct legal entity, "Invent DCU Limited".

The Assignee of the entire right, title and interest in the above-referenced patent application, Invent DCU Limited, having an address at Dublin 9, IRELAND, has the right to take action in this application by virtue of an assignment by the inventors to Allergan, Inc., recorded May 1, 1997 on reel 008481 and frame 0839, and an assignment from Allergan, Inc. to Invent DCU Limited, which assignment was recorded December 15, 2008 at Reel 022102, Frame 0979.

The undersigned is authorized to act on behalf of the Assignee.

Respectfully submitted,

Dated: 6/2/09

By: 
Richard Stokes
Chief Executive Officer
INVENT DCU LIMITED